Eisai may be the biggest loser, but it’s not the only loser with Belviq withdrawal Feb. 19, 2020 By Mari Serebrov No Comments A lot of development dollars are shed when the FDA withdraws approval or requests that a drug be withdrawn from the market because new potential risks have come to light. And it’s not just the brand company that feels the loss.Read More